| 应用 |
An ADP receptor inhibitor |
| 产品介绍 |
Is a member of the thienopyridine class of ADP receptor inhibitors |
| 备注 |
A novel platelet inhibitor |
| 生化机理 |
Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors. These agents reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. Prasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia |
| 别名 |
普拉格雷;5-[2-环丙基-1-(2-氟苯基)-2-氧乙基]-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基羧酸酯;CS 747;LY640315;5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl Acetate |
